The efficacy of intravitreal ranibizumab for the treatment of macular oedema secondary to retinal vein occlusions in a treatment-naive cohort: 6-month outcomes

被引：0
|
作者：
Laginaf, Masara [1 ]
Lewis, Adam [1 ]
Chandran, Manju [1 ]
Menon, Geeta [1 ]
机构：
[1] Frimley Hlth NHS Fdn Trust, Ophthalmol, Frimley, England
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2015年 / 56卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
204
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Ranibizumab and aflibercept intravitreal injection for treatment naive and refractory macular oedema in branch retinal vein occlusion
    Hogg, H. D. Jeffry
    Di Simplicio, Sandro
    Pearce, Mark S.
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2021, 31 (02) : 548 - 555
  • [2] Comment on: Ranibizumab and aflibercept intravitreal injection for treatment naive and refractory macular oedema in branch retinal vein occlusion
    Elkazza, Sumeia A.
    Hogg, H. D. Jeffry
    Di Simplicio, Sandro
    Dlay, Satnam S.
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2022, 32 (01) : NP303 - NP304
  • [3] Recurrence of macular edema in retinal vein occlusions after treatment with intravitreal ranibizumab (Lucentis)
    Karagiannis, Dimitrios A.
    Karampelas, Michael D.
    Soumplis, Vasileios M.
    Amariotakis, Christos
    Georgalas, Ilias
    Kandarakis, Artemios
    CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE, 2011, 46 (06): : 486 - 490
  • [4] Treatment of macular oedema secondary to retinal vein occlusions with Ranibizumab in a patient cohort with persistent macular oedema refractory to treatment with Bevacizumab or Ozurdex: Follow up over 12 months.
    Lewis, Adam
    Esposito, Fernando
    Chandran, Manju
    Menon, Geeta
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
  • [5] Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab
    T D Papakostas
    L Lim
    T van Zyl
    J B Miller
    B S Modjtahedi
    C M Andreoli
    D Wu
    L H Young
    I K Kim
    D G Vavvas
    D D Esmaili
    D Husain
    D Eliott
    L A Kim
    Eye, 2016, 30 : 79 - 84
  • [6] Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab
    Papakostas, T. D.
    Lim, L.
    van Zyl, T.
    Miller, J. B.
    Modjtahedi, B. S.
    Andreoli, C. M.
    Wu, D.
    Young, L. H.
    Kim, I. K.
    Vavvas, D. G.
    Esmaili, D. D.
    Husain, D.
    Eliott, D.
    Kim, L. A.
    EYE, 2016, 30 (01) : 79 - 84
  • [7] Visual and anatomical outcomes following intravitreal treatment of macular oedema secondary to retinal vein occlusion
    Tasos, Emmanuel
    Sharma, Pavel
    Karia, Janvi
    Menem, Dheyaedeen
    Katzakis, Michail
    Minos, Evangelos
    ACTA OPHTHALMOLOGICA, 2024, 102
  • [8] Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion
    Kreutzer, T. C.
    Alge, C. S.
    Wolf, A. H.
    Kook, D.
    Burger, J.
    Strauss, R.
    Kunze, C.
    Haritoglou, C.
    Kampik, A.
    Priglinger, S.
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2008, 92 (03) : 351 - 355
  • [9] Comment on: 'Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab'
    Calugaru, D.
    Calugaru, M.
    EYE, 2016, 30 (05) : 766 - 766
  • [10] Comparison of intravitreal ranibizumab and bevacizumab for the treatment of macular edema secondary to retinal vein occlusion
    Alex Yuan
    Baseer U.Ahmad
    David Xu
    Rishi P.Singh
    Peter K.Kaiser
    Daniel F.Martin
    Jonathan E.Sears
    Andrew P.Schachat
    Justis P.Ehlers
    International Journal of Ophthalmology, 2014, 7 (01) : 86 - 91
12345